

Clinical Policy: Lisocabtagene Maraleucel (Breyanzi)

Reference Number: CP.PHAR.483

Effective Date: 02.05.21

Last Review Date: 05.25

Line of Business: Commercial, HIM, Medicaid

[Coding Implications](#)[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

Description

Lisocabtagene maraleucel (Breyanzi[®]) is a CD19-directed genetically modified autologous T-cell immunotherapy.

FDA Approved Indication(s)

Breyanzi is indicated for the treatment of:

- Adult patients with large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B, who have:
 - Refractory disease to first-line chemoimmunotherapy or relapse within 12 months of first-line chemoimmunotherapy; or
 - Refractory disease to first-line chemoimmunotherapy or relapse after first-line chemoimmunotherapy and are not eligible for hematopoietic stem cell transplantation (HSCT) due to comorbidities or age; or
 - Relapsed or refractory disease after two or more lines of systemic therapy.
- Limitation of use: Breyanzi is not indicated for the treatment of patients with primary central nervous system (CNS) lymphoma.
- Adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have received at least 2 prior lines of therapy, including a Bruton tyrosine kinase inhibitor (BTKi) and a B-cell lymphoma 2 inhibitor (BCL-2i).*
- Adult patients with relapsed or refractory follicular lymphoma (FL) who have received 2 or more prior lines of systemic therapy.*
- Adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have received at least 2 prior lines of systemic therapy, including a BTKi.

** This indication is approved under accelerated approval based on response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).*

Policy/Criteria

Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

All requests reviewed under this policy **require medical director review**.

It is the policy of health plans affiliated with Centene Corporation[®] that Breyanzi is **medically necessary** when the following criteria are met:

I. Initial Approval Criteria

A. Large B-Cell Lymphoma* (must meet all):

**Only for initial treatment dose; subsequent doses will not be covered.*

1. Diagnosis of one of the following LBCL (a – h);
 - a. DLBCL;
 - b. DLBCL transformed from one of the following (i – v):
 - i. Follicular lymphoma;
 - ii. Nodal marginal zone lymphoma;
 - iii. Gastric mucosa-associated lymphoid tissue (MALT) lymphoma;
 - iv. Nongastric MALT Lymphoma (noncutaneous);
 - v. Splenic marginal zone lymphoma;
 - c. Primary mediastinal LBCL;
 - d. Follicular lymphoma grade 3B;
 - e. High-grade B-cell lymphomas;
 - f. Post-transplant lymphoproliferative disorders (B-cell type);
 - g. HIV-related DLBCL, primary effusion lymphoma, HHV8-positive DLBCL, and HIV-related plasmablastic lymphoma;
 - h. T cell/histiocyte-rich LBCL;
2. Prescribed by or in consultation with an oncologist or hematologist;
3. One of the following (a or b):
 - a. Age \geq 18 years;
 - b. Request is for primary mediastinal LBCL;
4. Request is for one of the following (a, b, or c):
 - a. Disease is refractory or member has relapsed after \geq 2 lines of systemic therapy that includes an anti-CD20 therapy (e.g., rituximab) and one anthracycline-containing regimen (e.g., doxorubicin);*
 - b. Disease that is refractory (defined as no complete remission) to or has relapsed (defined as complete remission followed by biopsy-proven disease relapse) no more than 12 months after first-line chemoimmunotherapy that included an anti-CD20 monoclonal antibody (e.g., rituximab*) and anthracycline-containing regimen (e.g., doxorubicin);
 - c. Member is not eligible for HSCT due to comorbidities or age (see *Appendix D* for examples) and disease is refractory (defined as no complete remission) to or has relapsed (defined as complete remission followed by biopsy-proven disease relapse) after first-line chemoimmunotherapy that included an anti-CD20 monoclonal antibody (e.g., rituximab*) and anthracycline-containing regimen (e.g., doxorubicin);

**Prior authorization may be required for rituximab*
5. Member does not have primary CNS disease;
6. Member has not previously received treatment with CAR T-cell immunotherapy (e.g., Abecma[®], Carvykti[™], Kymriah[™], Tecartus[™], Yescarta[™]);
7. Breyanzi is not prescribed concurrently with other CAR T-cell immunotherapy (e.g., Abecma, Carvykti, Kymriah, Tecartus, Yescarta);
8. Dose does not exceed 110×10^6 chimeric antigen receptor (CAR)-positive viable T cells.

Approval duration: 3 months (1 dose only, with 4 doses of tocilizumab (Actemra) if requested at up to 800 mg per dose)

B. Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma* (must meet all):

**Only for initial treatment dose; subsequent doses will not be covered.*

1. Diagnosis of relapsed or refractory CLL or SLL;
2. Prescribed by or in consultation with an oncologist or hematologist;
3. Age ≥ 18 years;
4. One of the following (a or b):
 - a. Member has measurable disease as evidenced by one of the following assessed within the last 30 days (i, ii, or iii):
 - i. Measurable lymph nodes ≥ 1.5 cm in the greatest transverse diameter;
 - ii. Hepatomegaly;
 - iii. Splenomegaly;
 - b. Demonstration of CLL cells in the peripheral blood by flow cytometry;
5. Member has received ≥ 2 prior lines of therapy (*see Appendix B for examples*) that include both of the following (a and b):
 - a. One BTKi (e.g., Brukinsa[®], Calquence[®], Imbruvica[®]);
 - b. One BCL2i (e.g., Venclexta[®]);
6. Member does not have active CNS involvement by malignancy or history or presence of clinically relevant CNS pathology (e.g., epilepsy, generalized seizure disorder, aphasia, stroke with current neurologic sequelae, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, cerebral edema, or psychosis);
7. Member has not previously received treatment with CAR T-cell immunotherapy (e.g., Abecma, Carvykti, Kymriah, Tecartus, Yescarta);
8. Breyanzi is not prescribed concurrently with other CAR T-cell immunotherapy (e.g., Abecma, Carvykti, Kymriah, Tecartus, Yescarta);
9. Dose does not exceed 110×10^6 CAR-positive viable T-cells.

**Prior authorization may be required.*

Approval duration: 3 months (1 dose only, with 4 doses of tocilizumab (Actemra) if requested at up to 800 mg per dose)

C. Follicular Lymphoma* (must meet all):

**Only for initial treatment dose; subsequent doses will not be covered.*

1. Diagnosis of FL grade 1, 2, or 3a;
2. Prescribed by or in consultation with an oncologist or hematologist;
3. Age ≥ 18 years;
4. Disease is relapsed/refractory after ≥ 2 lines of systemic therapy that includes a combination of an anti-CD20 monoclonal antibody (e.g., rituximab or Gazyva[®]) and an alkylating agent (e.g., bendamustine, cyclophosphamide, chlorambucil)*;
5. Member does not have CNS-only involvement by malignancy (secondary CNS involvement is allowed);
6. Member does not have history or presence of clinically relevant CNS pathology (e.g., epilepsy, generalized seizure disorder, aphasia, stroke with current neurologic sequelae, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, cerebral edema, or psychosis);

**Prior authorization may be required*

7. Member has not previously received treatment with CAR T-cell immunotherapy (e.g., Abecma, Carvykti, Kymriah, Tecartus, Yescarta);
8. Breyanzi is not prescribed concurrently with other CAR T-cell immunotherapy (e.g., Abecma, Carvykti, Kymriah, Tecartus, Yescarta);
9. Dose does not exceed 100×10^6 CAR-positive viable T cells.

Approval duration: 3 months (1 dose only, with 4 doses of tocilizumab (Actemra) if requested at up to 800 mg per dose)

D. Mantle Cell Lymphoma* (must meet all):

**Only for initial treatment dose; subsequent doses will not be covered.*

1. Diagnosis of relapsed or refractory MCL;
2. Prescribed by or in consultation with an oncologist or hematologist;
3. Age ≥ 18 years;
4. Member has previously received ≥ 2 prior lines of systemic therapy that included all the following (a, b, and c):
 - a. Anti-CD20 monoclonal antibody therapy (e.g., rituximab);
 - b. BTKi (e.g., Imbruvica, Calquence, Brukinsa, Jaypirca[®]);
 - c. Alkylating agent (e.g., bendamustine, cyclophosphamide, platinum [carboplatin, cisplatin, or oxaliplatin]);
5. Member does not have CNS-only involvement by malignancy (secondary CNS involvement is allowed);
6. Member does not have history or presence of clinically relevant CNS pathology (e.g., epilepsy, generalized seizure disorder, aphasia, stroke with current neurologic sequelae, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, cerebral edema, or psychosis);
7. Member has not previously received treatment with CAR T-cell immunotherapy (e.g., Abecma, Carvykti, Kymriah, Tecartus, Yescarta);
8. Breyanzi is not prescribed concurrently with other CAR T-cell immunotherapy (e.g., Abecma, Carvykti, Kymriah, Tecartus, Yescarta);
9. Dose does not exceed 100×10^6 CAR-positive viable T cells.

Approval duration: 3 months (1 dose only, with 4 doses of tocilizumab (Actemra) if requested at up to 800 mg per dose)

E. Other diagnoses/indications (must meet 1 or 2):

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one of the following policies (a or b):
 - a. For drugs on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the no coverage criteria policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.33 for health insurance marketplace, and CP.PMN.255 for Medicaid; or
 - b. For drugs NOT on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the non-formulary policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.103 for health insurance marketplace, and CP.PMN.16 for Medicaid; or

2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace, and CP.PMN.53 for Medicaid.

II. Continued Therapy

A. All Indications in Section I:

1. Continued therapy will not be authorized as Breyanzi is indicated to be dosed one time only.

Approval duration: Not applicable

B. Other diagnoses/indications (must meet 1 or 2):

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one of the following policies (a or b):
 - a. For drugs on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the no coverage criteria policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.33 for health insurance marketplace, and CP.PMN.255 for Medicaid; or
 - b. For drugs NOT on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the non-formulary policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.103 for health insurance marketplace, and CP.PMN.16 for Medicaid; or
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace, and CP.PMN.53 for Medicaid.

III. Diagnoses/Indications for which coverage is NOT authorized:

- A.** Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace, and CP.PMN.53 for Medicaid or evidence of coverage documents;
- B.** Primary CNS disease.

IV. Appendices/General Information

Appendix A: Abbreviation/Acronym Key

ALC: absolute lymphocyte count
BTKi: Bruton tyrosine kinase inhibitor
BCL2i: B-cell lymphoma 2 inhibitor
CLL: chronic lymphocytic leukemia
CAR: chimeric antigen receptor
CNS: central nervous system
CRS: cytokine release syndrome

DLBCL: diffuse large B-cell lymphoma
FDA: Food and Drug Administration
FL: follicular lymphoma
HSCT: hematopoietic stem cell transplantation
LBCL: large B-cell lymphoma
MALT: mucosa-associated lymphoid tissue

MCL: mantle cell lymphoma

SLL: small lymphocytic lymphoma

Appendix B: Therapeutic Alternatives

This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent for all relevant lines of business and may require prior authorization.

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
LBCL: First-Line Treatment Regimens		
RCHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone)	Varies	Varies
RCEPP (rituximab, cyclophosphamide, etoposide, prednisone, procarbazine)	Varies	Varies
RCDOF (rituximab, cyclophosphamide, liposomal doxorubicin, vincristine, prednisone)	Varies	Varies
DA-EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin) + rituximab	Varies	Varies
RCEOP (rituximab, cyclophosphamide, etoposide, vincristine, prednisone)	Varies	Varies
RGCVP (rituximab, gemcitabine, cyclophosphamide, vincristine, prednisone)	Varies	Varies
LBCL: Second-Line Treatment Regimens		
Bendeka [®] (bendamustine) ± rituximab	Varies	Varies
CEPP (cyclophosphamide, etoposide, prednisone, procarbazine) ± rituximab	Varies	Varies
CEOP (cyclophosphamide, etoposide, vincristine, prednisone) ± rituximab	Varies	Varies
DA-EPOCH ± rituximab	Varies	Varies
GDP (gemcitabine, dexamethasone, cisplatin) ± rituximab	Varies	Varies
gemcitabine, dexamethasone, carboplatin ± rituximab	Varies	Varies
GemOx (gemcitabine, oxaliplatin) ± rituximab	Varies	Varies
gemcitabine, vinorelbine ± rituximab	Varies	Varies
lenalidomide ± rituximab	Varies	Varies
Rituximab (Riabni [™] , Rituxan [®] , Ruxience [®] , Truxima [®])	Varies	Varies
DHAP (dexamethasone, cisplatin, cytarabine) ± rituximab	Varies	Varies
DHAX (dexamethasone, cytarabine, oxaliplatin) ± rituximab	Varies	Varies
ESHAP (etoposide, methylprednisolone, cytarabine, cisplatin) ± rituximab	Varies	Varies
ICE (ifosfamide, carboplatin, etoposide) ± rituximab	Varies	Varies
MINE (mesna, ifosfamide, mitoxantrone, etoposide) ± rituximab	Varies	Varies
CLL/SLL: First-Line Therapies		

Calquence (acalabrutinib) ± Gazyva [®] (obinutuzumab)	Varies	Varies
Venclexta [®] (venetoclax) + Gazyva (obinutuzumab)	Varies	Varies
Brukina (zanubrutinib)	160 mg PO BID or 320 mg PO QD	320 mg/day 640 mg/day when used with a moderate CYP3A4 inducer
Imbruvica [®] (ibrutinib)	420 mg PO QD	420 mg/day
Imbruvica (ibrutinib) + Gazyva (obinutuzumab)	Varies	Varies
Imbruvica (ibrutinib) + rituximab	Varies	Varies
Imbruvica (ibrutinib) + Venclexta (venetoclax)	Varies	Varies
CLL/SLL: Second-Line or Third-Line Therapies		
Calquence (acalabrutinib)	100 mg PO BID	400 mg/day
Venclexta (venetoclax) ± rituximab	Varies	Varies
Brukina (zanubrutinib)	160 mg PO BID or 320 mg PO QD	320 mg/day 640 mg/day when used with a moderate CYP3A4 inducer
Imbruvica (ibrutinib)	420 mg PO QD	420 mg/day
CLL/SLL: Therapies for Relapsed or Refractory Disease After Prior BTKi- and BCL2i-Based Regimens		
Copiktra [®] (duvelisib)	25 mg PO BID	50 mg/day
Zydelig [®] (idelalisib) ± rituximab	150 mg PO BID	300 mg/day
Jaypirca [™] (pirtobrutinib)	200 mg PO QD	200 mg/day
FCR (fludarabine, cyclophosphamide, rituximab)	Varies	Varies
Revlimid [®] (lenalidomide) ± rituximab	Varies	Varies
Gazyva (obinutuzumab)	100 mg IV on day 1, 900 mg IV on day 2 of cycle 1, then 1,000 mg IV on days 8 and 15 of cycle 1; begin the next cycle of therapy on day 29. For cycles 2 to 6, give 1,000 mg IV on day 1 repeated every 28 days.	See regimen
Campath [®] (alemtuzumab) ± rituximab	30 mg/day IV three times per week for 12 weeks	See regimen

High-dose methylprednisolone ± rituximab or Gazyva [®] (obinutuzumab)	Varies	Varies
FL First-Line and Second-Line + Subsequent Treatment Regimens		
bendamustine + (Gazyva [®] (obinutuzumab) or rituximab)	Varies	Varies
CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) + (Gazyva [®] (obinutuzumab) or rituximab)	Varies	Varies
CVP (cyclophosphamide, vincristine, prednisone) + Gazyva [®] (obinutuzumab) or rituximab	Varies	Varies
rituximab ± (lenalidomide, chlorambucil, or cyclophosphamide)	Varies	Varies
rituximab	Varies	Varies
Gazyva [®] (obinutuzumab)	Varies	Varies
Zevalin [®] (ibritumomab tiuxetan)	Varies	Varies
MCL		
HyperCVAD (cyclophosphamide, vincristine, doxorubicin, dexamethasone/methotrexate/ cytarabine) + rituximab	Varies	Varies
NORDIC (rituximab + cyclophosphamide, vincristine, doxorubicin, prednisone/rituximab + cytarabine)	Varies	Varies
RCHOP/RDHAP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone)/(rituximab, dexamethasone, cisplatin, cytarabine)	Varies	Varies
RDHA (rituximab, dexamethasone, cytarabine) + platinum (carboplatin, cisplatin, or oxaliplatin)	Varies	Varies
RCHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone)	Varies	Varies
Bendeka [®] (bendamustine) ± rituximab	Varies	Varies
VR-CAP (bortezomib, rituximab, cyclophosphamide, doxorubicin, prednisone)	Varies	Varies
Revlimid [®] (lenalidomide) + rituximab	Varies	Varies
bortezomib ± rituximab	Varies	Varies
lenalidomide ± rituximab	Varies	Varies
Imbruvica [®] (ibrutinib) ± rituximab	560 mg PO QD	560 mg/day
Calquence [®] (acalabrutinib)	100 mg PO BID	400 mg/day
Brukina [®] (zanubrutinib)	160 mg PO BID or 320 mg PO QD	320 mg/day

Jaypirca [®] (pirtobrutinib)	200 mg PO QD	200 mg PO QD
Venclexta [®] (venetoclax)	20 mg/day for week 1, 50 mg/day for week 2, 100 mg/day for week 3, 200 mg/day for week 4, 400 mg/day for week 5. Week 6 and thereafter: 800 mg/day	800 mg/day

Therapeutic alternatives are listed as Brand name[®] (generic) when the drug is available by brand name only and generic (Brand name[®]) when the drug is available by both brand and generic.

Appendix C: Contraindications/Boxed Warnings

- Contraindication(s): none reported
- Boxed warning(s): cytokine release syndrome, neurologic toxicities, and secondary hematological malignancies

Appendix D: General Information

- Patients with primary CNS disease were excluded from the TRANSCEND NHL 001 trial. For primary CNS lymphoma, NCCN treatment guidelines for CNS cancers recommend a high-dose methotrexate induction based regimen or whole brain radiation therapy, and consolidation therapy with high-dose chemotherapy with stem cell rescue, high-dose cytarabine with or without etoposide, low dose whole brain radiation therapy, or continuation with monthly high-dose methotrexate-based regimen.
- In the TRANSCEND NHL 001 trial, three of six patients in the efficacy-evaluable set with secondary CNS lymphoma achieved a complete response.
- No prespecified threshold for blood counts, including absolute lymphocyte count, was required for enrollment in the TRANSCEND NHL 001 trial.
- The PILOT study evaluated transplant-ineligible patients with relapsed or refractory LBCL after one line of chemoimmunotherapy. The study required at least one of the following criteria to identify patients who were not eligible for high-dose therapy and autologous HSCT: age ≥ 70 years, adjusted diffusing capacity of the lung for carbon monoxide (DLCO) $\leq 60\%$; left ventricular ejection fraction (LVEF) $< 50\%$; creatinine clearance < 60 mL/min; aspartate transaminase (AST) or alanine aminotransferase (ALT) greater than two times the upper limit or normal, or Eastern Cooperative Oncology Group (ECOG) performance status of 2 (capable of all self-care but unable to carry out any work activities; up and about $> 50\%$ of waking hours).

V. Dosage and Administration

Indication	Dosing Regimen	Maximum Dose
LBCL after two or more lines of therapy	Target dose: 50 to 110 x 10 ⁶ CAR-positive viable T cells	110 x 10 ⁶ CAR-positive viable T cells
LBCL after one line of therapy, CLL/SLL, FL, MCL	Target dose: 90 to 110 x 10 ⁶ CAR-positive viable T cells	110 x 10 ⁶ CAR-positive viable T cells

VI. Product Availability

Single-dose 5 mL vial: frozen suspension of genetically modified autologous T-cells labeled for the specific recipient

VII. References

1. Breyanzi Prescribing Information. Bothell, WA: Juno Therapeutics, Inc.; May 2024. Available at: https://packageinserts.bms.com/pi/pi_breyanzi.pdf. Accessed January 17, 2025.
2. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Identifier NCT02631044, Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001); 3 March 2023. Available at: <https://clinicaltrials.gov/ct2/show/NCT02631044>. Accessed February 12, 2025.
3. Abramson JS, Palomba ML, Gordon LI, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. *Lancet*. 2020 September 19; 396: 839-852.
4. National Comprehensive Cancer Network. B-cell Lymphomas Version 2.2025. Available at: https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf. Accessed February 12, 2025.
5. National Comprehensive Cancer Network. Pediatric Aggressive Mature B-cell Lymphomas Version 2.2024. Available at: https://www.nccn.org/professionals/physician_gls/pdf/ped_b-cell.pdf. Accessed February 12, 2025.
6. National Comprehensive Cancer Network Drug and Biologics Compendium. Available at http://www.nccn.org/professionals/drug_compendium. Accessed February 12, 2025.
7. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Identifier NCT03575351, A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas (TRANSFORM); 15, November 2023. Available at: <https://www.clinicaltrials.gov/ct2/show/NCT03575351>. Accessed February 12, 2025.
8. Kamdar M, Solomon SR, Arnason JE, et al. Lisocabtagene Maraleucel Versus Standard of Care with Salvage Chemotherapy Followed By Autologous Stem Cell Transplantation As Second-Line Treatment in Patients with Relapsed or Refractory Large B-Cell Lymphoma (TRANSFORM): Results from an interim analysis of an open-label, randomized, phase 3 trial. *Lancet* 2022; 399: 2294-308.
9. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Identifier NCT03483103, Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006); 20, December 2023. Available at: <https://clinicaltrials.gov/ct2/show/NCT03483103>. Accessed February 12, 2025.
10. Sehgal AR, Hildebrandt G, Ghosh N, et al. 2020 ASCO Annual Meeting I, Meeting Abstract: Lisocabtagene maraleucel (liso-cel) for treatment of second-line (2L) transplant noneligible (TNE) relapsed/refractory (R/R) aggressive large B-cell non-Hodgkin lymphoma (NHL): Updated results from the PILOT study. *Journal of Clinical Oncology*. 20, May 2020; 38 (15): 8040.
11. Sehgal A, Hoda D, Riedell PA, et al. Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study. *Lancet Oncol*. 2022 Aug; 23 (8): 1066-1077.

12. Siddiqi T, Maloney DG, Kenderian SS, et al. Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study. *Lancet*. 2023 Aug 19;402(10402):641-654.
13. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Identifier NCT03331198, Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL); 29, August 2023. Available at: <https://clinicaltrials.gov/study/NCT03331198>. Accessed February 12, 2025.
14. Siddiqi T, Maloney DG, Kenderian S, et al. Lisocabtagene maraleucel (liso-cel) in R/R chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Primary analysis of TRANSCEND CLL 004. Meeting Abstract: 2023 ASCO Annual Meeting I. *Journal of Clinical Oncology* 2023 41:16_suppl, 7501.
15. National Comprehensive Cancer Network. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Version 2.2025. Available at: https://www.nccn.org/professionals/physician_gls/pdf/cll.pdf. Accessed February 12, 2025.
16. Wang M, Siddiqi T, Gordon LI, et al. Lisocabtagene Maraleucel in Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis of the Mantle Cell Lymphoma Cohort From TRANSCEND NHL 001, a Phase I Multicenter Seamless Design Study. *J Clin Oncol*. 2023 Dec 10; JCO2302214. doi: 10.1200/JCO.23.02214.
17. Abramson JS, Palomba ML, Gordon LI, et al. Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001. *Blood*. 2024 Feb 1;143(5):404-416.
18. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Identifier NCT04245839, A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL) (TRANSCEND FL); 30, November 2023. Available at: <https://clinicaltrials.gov/study/NCT04245839>. Accessed February 12, 2025.
19. BMS Press Release: Bristol Myers Squibb's Breyanzi (lisocabtagene maraleucel) Delivers Deep and Durable Responses in Relapsed or Refractory Follicular Lymphoma and Mantle Cell Lymphoma in TRANSCEND Clinical Trials Presented at ICML 2023. Available at: <https://news.bms.com/news/details/2023/Bristol-Myers-Squibbs-Breyanzi-lisocabtagene-maraleucel-Delivers-Deep-and-Durable-Responses-in-Relapsed-or-Refractory-Follicular-Lymphoma-and-Mantle-Cell-Lymphoma-in-TRANSCEND-Clinical-Trials-Presented-at-ICML-2023/default.aspx>. Accessed February 12, 2025.
20. Morschhauser F, Dahiya S, Palomba ML, et al. Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study. *Nat Med*. 2024 Jun 3. doi: 10.1038/s41591-024-02986-9.

Coding Implications

Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

HCPSC Codes	Description
Q2054	Lisocabtagene maraleucel, up to 110 million autologous anti-CD 19 CAR-positive viable T cells, including leukapheresis and dose preparation procedures, per therapeutic dose

Reviews, Revisions, and Approvals	Date	P&T Approval Date
Drug is now FDA approved – criteria updated per FDA labeling; removed minimum absolute lymphocyte count requirement; updated reference for HIM off-label use to HIM.PA.154 (replaces HIM.PHAR.21); references reviewed and updated; Added disclaimer under Policy/Criteria “All requests reviewed under this policy require medical director review.”	02.08.21	05.21
Clarified per NCCN Compendium additional DLBCL transformed diseases; added supported use for AIDS-related primary effusion lymphoma.	05.27.21	08.21
2Q 2022 annual review: per NCCN added additional AIDS-related uses in diffuse large B-cell lymphoma and HHV8-positive diffuse large B-cell lymphoma; updated HCPSC codes; added pre-emptive indication for relapsed/refractory LBCL in the second-line setting; references reviewed and updated.	03.09.22	05.22
RT4: converted pre-emptive criteria to FDA-approved status per updated prescribing information for relapsed/refractory LBCL in the second-line setting.	07.07.22	08.22
Template changes applied to other diagnoses/indications and continued therapy section.	10.03.22	
Doxorubicin spelling corrected in Appendix B.	10.19.22	11.22
2Q 2023 annual review: no significant changes; modified AIDS-related DLBCL to HIV-related per NCCN Compendium; references reviewed and updated.	01.30.23	05.23
2Q 2024 annual review: for T-cell/histiocyte-rich LBCL removed requirement for use as second line therapy; references reviewed and updated. RT2: added new indication for CLL/SLL; updated boxed warnings to include secondary hematological malignancies per updated prescribing information.	04.09.24	05.24
RT4: added new indications for FL and MCL.	06.04.24	
2Q 2025 annual review: added bypass for age requirement for primary mediastinal LBCL per NCCN Guidelines in Pediatric Aggressive Mature B-Cell Lymphomas; added NCCN Compendium supported use in HIV-related plasmablastic lymphoma; references reviewed and updated.	01.17.25	05.25

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

Note: For Medicaid members, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

©2020 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene[®] and Centene Corporation[®] are registered trademarks exclusively owned by Centene Corporation.